Skip to content

News

KVIA-TV ABC-7 Features OCRA-Funded Research Developing Nanotechnology for Ovarian Cancer Detection

KVIA-TV ABC-7 Features OCRA-Funded Research Developing Nanotechnology for Ovarian Cancer Detection

KVIA-TV ABC-7 News El Paso recently spotlighted the groundbreaking work of OCRA-funded researcher Daniel Heller, PhD of Memorial Sloan Kettering Cancer Center, whose research lab is working to develop a liquid biopsy that uses nanotechnology and artificial intelligence (AI) to detect ovarian cancer earlier. We’re developing a liquid biopsy that uses nano sensors and AI … Continued

OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients

OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients

This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help understand ovarian cancer, cervical cancer, or … Continued

FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC) who have a KRAS mutation.  The approval is based on the results of the Phase 2 RAMP 201 clinical … Continued

OCRA’s Early Career Investigator Grant Recipients

OCRA’s Early Career Investigator Grant Recipients

Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These grants are essential to ensure that promising researchers with an established commitment to ovarian and related gynecologic cancers can continue to focus their efforts on … Continued

CDC Report Shows Drop in Cervical Precancer Among HPV Vaccinated Age Group

CDC Report Shows Drop in Cervical Precancer Among HPV Vaccinated Age Group

Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease Control and Prevention (CDC). The report notes that women in this age group are those most likely to have received the HPV vaccine. Read the … Continued

Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research

Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research

Ovarian Cancer Research Alliance (OCRA), the largest global organization dedicated to advancing ovarian and related gynecologic cancer research, announced today the recipients of two prizes awarded for noteworthy work in the field of ovarian cancer research. One honoree received the 2024 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research in recognition of his groundbreaking … Continued

The Overview: January 2025

The Overview: January 2025

OCRA Joins Forces With Rivkin Center for Ovarian Cancer Research Ovarian Cancer Research Alliance (OCRA) has announced that the Rivkin Center for Ovarian Cancer Research will join with OCRA effective April 1, 2025. This historic collaboration unites two respected organizations committed to advancing research for a cure for ovarian and all gynecologic cancers. “OCRA has always … Continued

How OCRA-Funded Research is Harnessing AI and Nanotechnology for Earlier Ovarian Cancer Detection, a Conversation with Clarke’s Closer Look

How OCRA-Funded Research is Harnessing AI and Nanotechnology for Earlier Ovarian Cancer Detection, a Conversation with Clarke’s Closer Look

In a new interview with journalist Marcel Clarke for Clarke’s Closer Look, OCRA grantee Dr. Daniel Heller of Memorial Sloan Kettering Cancer Center discusses how his lab is utilizing artificial intelligence (AI) to develop a cutting-edge blood test to detect ovarian cancer at its earliest stages. This OCRA-funded study is in partnership with Microsoft AI … Continued

OCRA-Funded Research Identifies Promising Therapeutic Strategy to Improve Immune Response Against Ovarian Cancer

OCRA-Funded Research Identifies Promising Therapeutic Strategy to Improve Immune Response Against Ovarian Cancer

A study recently published in Science Advances and supported in part by Ovarian Cancer Research Alliance has advanced scientists’ understanding of how to potentially overcome immune evasion in ovarian cancer. The research team involved current and former Memorial Sloan Kettering Cancer Center researchers, including OCRA grantee Melica Brodeur MD, MSc, now at McGill University, who … Continued

BBC Features OCRA-Funded Research in AI Breakthroughs Series

BBC Features OCRA-Funded Research in AI Breakthroughs Series

OCRA-funded research using artificial intelligence (AI) for ovarian cancer early detection was highlighted in the BBC’s six-part series on how AI is transforming medicine. Dr. Daniel Heller, an OCRA-funded researcher at Memorial Sloan Kettering Cancer Center, shared how his team is using AI and nanotechnology to develop a cutting-edge blood test for early ovarian cancer … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.